1 Identification of small regulatory RNAs involved in persister 2 formation

3 Shanshan Zhang¹, Shuang Liu¹, Nan Wu¹, Wenhong Zhang^{1*} and Ying Zhang^{2*}

4 ¹ Key Lab of Molecular Virology, Institute of Medical Microbiology, Department of
5 Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China,

6 ² Key Lab of Molecular Virology, Institute of Medical Microbiology, Department of
7 Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China;
8 Department of Molecular Microbiology and Immunology, Bloomberg School of
9 Public Health, Johns Hopkins University, Baltimore, MD, USA

10 *Correspondence: WH Zhang, E-mail: zhangwenhong@fudan.edu.cn; Y Zhang,
11 E-mail: yzhang@jhsph.edu

12 Abstract

13 Small regulatory RNA (srRNA) is widely distributed in three kingdoms of life and
14 fulfills functions in many aspects of cellular life, but their role in bacterial persistence
15 remains unknown. In this study, we comprehensively interrogated the expression
16 levels of the known srRNAs on three critical time points, stage 1 (S1) where no
17 persisters are formed, stage 2 (S2) where persisters are beginning to appear, and stage
18 3 (S3) where persister numbers increase significantly. Three upregulated srRNAs
19 (OmrB, an outer member associated srRNA; RdlB, a swarming motility and curli
20 expression regulator; McaS, a flagellar motility and biofilm formation regulator)
21 overlapping in S2/S1 and S3/S1, together with the other four upregulated srRNAs
22 (MicF, a ribosome binding inhibitor; MicL, an outer membrane associated srRNA;
23 RybB, a cell envelope stress regulator; RydB, regulator of a global regulator RpoS) in
24 S2/S1 are of special interest. By constructing deletion mutants and overexpression
25 strains in uropathogenic *E. coli* strain UTI89, we tested their persister-formation
26 capabilities in log phase and stationary phase cultures exposed to antibiotics
27 (gentamicin, cefotaxime and levofloxacin) and stresses (heat, hyperosmosis, H₂O₂,
28 and acid). The results of the deletion mutant studies showed that all the seven
29 identified srRNAs have varying effects on persister formation with different antibiotics
30 or stresses. Moreover, we found all the deletion mutants of these srRNAs have
31 reduced biofilm formation. Additionally, except the McaS and the RydB
32 overexpression strains, all of the srRNAs overexpression strains demonstrated
33 increased persister-formation in antibiotic and stress persister assays, confirming the
34 role of these srRNAs in persistence. Together, we identified seven srRNAs (OmrB,
35 RdlB, McaS, MicF, MicL, RybB, and RydB) that are involved in type II persister

formation for the first time. These findings provide convincing evidence for a new level of rapid persistence regulation via srRNA and furnish novel therapeutic targets for intervention.

Keywords: small RNA, persister, antibiotic, stress, uropathogenic *Escherichia coli*, biofilm

Introduction

Persisters have drawn wide attention since they can be identified in almost every bacterial species, even in fungi and eukaryotic human cancer cells [1-5]. They refer to a small subpopulation of dormant cells that can survive lethal antibiotics or stresses and regain susceptibilities when regrowing in fresh medium [6-8]. Persisters account for the recalcitrance of treatment of many persistent bacterial infections and can facilitate the emergence of antibiotic resistant bacteria [7-11]. Consequently, persisters pose great challenges for effective treatment of many bacterial infections

Persisters are divided into, type I and type II persisters [12]. Type I persisters stem from the stationary phase, while type II persisters are induced by triggering environmental signals as the cultures grow older from log phase to stationary phase. Unlike type I persister, type II persisters make up a great majority of the persisters in the stationary phase [13] and we consider them very important for understanding persister-formation mechanisms. Although various persister genes have been identified, how persisters are formed from a growing cell to a persister cell is still unclear.

Small regulatory RNAs (srRNAs) are widely spread in three domains of life, Archaea, Bacteria, and Eukaryotes [14]. In *Escherichia coli* (*E. coli*), they are non-coding, 50–500 nucleotides in length and synthesized under specific conditions [15-17]. srRNAs function in stress response, virulence regulation, biofilm formation, cell motility, uptake and metabolisms [18-22]. Though various functions have been described, their roles in persistence remain unclear. It is critical to determine the persister-formation capacities of srRNAs as they can respond to external signals quickly without protein synthesis.

To study the role of srRNA in persistence, especially those related with the emergence of type II persisters, we systematically interrogated the expression levels of the known srRNAs at three important timepoints where persisters switch from zero to high numbers. By constructing deletion mutants and overexpression strains of the candidate srRNAs and challenging them with different antibiotics and stresses, we identified seven srRNAs which play critical roles in regulating persister-formation.

Materials and methods

72 **Bacterial strains, plasmids, and growth conditions**

73 *E. coli* K12 strain W3110 and uropathogenic *E. coli* strain UTI89 as well as its
 74 derivatives were used in our experiments. The plasmid pBAD202 was used to
 75 construct the overexpression strains. The medium was supplemented with kanamycin
 76 (50 µg/mL) or chloramphenicol (25 µg/mL) to maintain resistance where necessary.
 77 Bacteria stored in -80°C were transferred to fresh Luria-Bertani (LB) broth (10 g
 78 Bacto-tryptone, 5 g yeast extract, and 10 g NaCl/liter) at 37°C, 200 rpm and grew
 79 overnight before use. Bacteria were diluted 1:1000 and routinely regrown in LB broth
 80 at 37°C, 200 rpm in our experiments, unless otherwise stated.

81 **Construction of deletion mutants and overexpression strains**

82 sRNA deletion mutants were constructed successfully using the λ Red recombination
 83 system as described by Datsenko and Wanner [23]. Primers used to amplify all
 84 knockout-DNA fragments and to verify the correct constructs by polymerase chain
 85 reaction (PCR) are shown in Tables S1 and S2.

86 The arabinose-inducible plasmid pBAD202 was used to construct overexpression
 87 strains [24]. The primers used for the construction of the plasmid are listed in Table
 88 S3. Genes were amplified with primers and digested with the restriction enzymes
 89 *Nco*I and *Eco*RI (New England Biolabs). pBAD202 was also digested with the two
 90 enzymes and used for ligation with the PCR fragments using the T4 DNA ligase (New
 91 England Biolabs). The new constructs along with the empty vector, pBAD202, were
 92 transformed into parent strain UTI89 for overexpression experiments. The deletion
 93 mutants and overexpression strains were verified by DNA sequencing. Arabinose
 94 (0.1%) was added to the cultures of overexpression strains to induce the conditional
 95 expression of candidate genes [3].

96 **RNA isolation and quantitative real time-PCR (RT-PCR)**

97 Bacteria were routinely cultured in LB medium followed by centrifugation at 4°C,
 98 5000 rpm to remove the supernatant. RNeasy Protect Bacteria Reagent (Qiagen) was
 99 added to resuspended cell suspensions immediately. Total RNA was isolated from
 100 cells using bacterial RNA kit (Omega Bio-tek) according to the manufacturer's
 101 protocol. Standardized total RNA was converted to cDNA using PrimeScript TMRT
 102 reagent Kit with gDNA Eraser (Takara) as described by the manufacturer. cDNA was
 103 then used as template to perform RT-PCR on an Applied Biosystems 7500 real-time
 104 instrument. The 16S rRNA gene *rrsB* was used as the reference gene.

105 **Persister assay**

106 Persister levels were determined by counting the number of colony forming units
 107 (CFUs) that grew on LB agar plates without antibiotics following exposure to

antibiotics, washing, and serial dilutions as previously described [3]. The antibiotics levofloxacin (5 µg/mL), cefotaxime (128 µg/mL), gentamicin (30 µg/mL) were added directly to cultures at the exponential phase (3 h of cultivation, ~10⁸ CFU/ mL) or stationary phase (10 h of cultivation, ~10⁹ CFU/ mL). Aliquots of the bacterial cultures were incubated at 37°C at different time points. To determine CFU, cultures were washed in phosphate-buffered saline before plating on LB plates in the absence of antibiotics [25].

Susceptibility to other stresses in exposure assays

For acid stress (pH 3.0) and hyperosmosis stress (NaCl, 4 M), cultures were washed twice and resuspended in the same volume of the corresponding LB medium (pH 3.0, adjusted with HCl or NaCl, 4 M, respectively). For heat shock, bacteria were put in a water bath at 53°C for 1 h or 2 h. For the oxidative stress test, stationary phase cultures were diluted 1:100 with LB and exposed to hydrogen peroxide (H₂O₂) at a final concentration of 10 mM for up to 30 minutes. After exposure to various stresses, bacteria were washed in phosphate-buffered saline before plating on LB plates in the absence of antibiotics to determine CFU count [25, 26].

Biofilm assay

Biofilm assays were performed as described previously [27]. Overnight cultures grown in LB were diluted to OD₆₀₀ of ~0.05 in LB. A 200 µl aliquot of the diluted culture was added to each well of a 96-well polystyrene microtiter plate (Sermo, USA) and inoculated at 37°C without shaking for 24 h. The planktonic cells were determined by measuring OD₆₀₀ using the SpectraMax Paradigm multi-mode detection platform (Applied Biosystems). The plate was washed with distilled water to remove the planktonic cells and retained with 220 µl of 0.1% crystal violet for 10 min. Unattached dye was rinsed away by washing with water for three times. Then the plate was dried and added with acetic acid (30%) to solubilize fixed crystal violet. The fixed biofilms were detected at OD₅₇₀ and normalized by OD₆₀₀.

Statistical analysis

All experiments were performed at least in triplicate. The Mann-Whitney *U* test (non – parametric tests) in Prism 6.0 software (GraphPad, La Jolla, CA, USA) was used to analyze the data (UTI89 vs. mutants) to determine the statistical significance of differences [28]. Error bars indicated standard deviations, and all data were presented as the mean ± standard deviation. A *P* < 0.05 was considered statistically significant.

Results

Determination of three timepoints for type II persisters upon ampicillin treatment

Type II persisters are induced by fluctuating environmental signals, not originated from passage through the stationary phase [12]. Thus, capturing the timepoints that type II persisters appear and increase significantly is very important to study the genes involved in type II persister formation. In order to minimize interference with type I persisters, *E. coli* strain W3110 overnight cultures were diluted to a very high dilution 1:10⁵ into fresh LB medium and then incubated at 37°C, with shaking at 100 rpm. Aliquots of bacteria were removed and exposed to ampicillin (100 µg/mL) for 3 hours to determine the persister numbers. We found that no persisters existed in the first three hours. However, persisters started to appear at the 4th hour, with 2 ~3 CFU/mL being detected. At the 5th hour, the persister number increased to ~ 42 CFU/mL (Fig. 1A). Meanwhile, the initial cell numbers at the 3rd, 4th and 5th hours were also counted, with bacterial concentration reaching ~2.1×10⁵, ~1.4×10⁶, ~1.1×10⁷ respectively (Fig. 1B). Results indicated that cell density is associated with the emergence of persisters. We referred to the 3rd hour as stage 1 (S1) where no persisters were present at this time point. The 4th hour is referred to as stage 2 (S2) where persisters were just beginning to appear, and the 5th hour is referred to as stage 3 (S3) where persister numbers increased significantly at this timepoint. S1, S2 and S3 are three important timepoints we used to identify genes associated with type II persister formation (see below).

Different expression levels of small regulatory RNAs in S1, S2, S3

To study the expression levels of srRNAs at the timepoints when persisters first appeared and then increased, we determined the expression levels of all the 57 srRNAs in the comprehensive EcoCyc database [29]. We found eight upregulated srRNAs (MicF, MgrR, MicL, OmrB, RdlB, McaS, RybB, RydB) (Fig. 2A) and 16 downregulated srRNAs (DicF, GadY, GlmZ, GlmY, IstR-1, OxyS, SgrS, SymR, SsrS, ArrS, FnrS, Och5, OhsC, RyfA, RyfD, RyeB) when comparing expression levels of S2 with S1. Six upregulated srRNAs (OmrB, RseX, McaS, MgrR, MicA, RdlB) (Fig. 2B) and 17 downregulated srRNAs (GadY, GlmZ, GlmY, IstR-1, OmrA, OxyS, RdlD, RybB, SgrS, SsrS, FnrS, Och5, RyfA, RyfD, RyeB, SibD, SibE) were detected when comparing expression levels of S3 with S1. Similarly, three upregulated srRNAs (DicF, ArrS, RyeG) and seven downregulated srRNAs (DsrA, GadY, RdlD, RybB, RydB, RyfA, SibE) were observed when comparing expression levels of S3 with S2. Target genes with known functions of the upregulated srRNAs are shown in Table 1. Pathways of these target genes comprise energy production, transport system, TA module, biofilm formation, global regulator, protease, trans-translation system, efflux pump that belong to known persister pathways [7], indicating the upregulated srRNAs might participate in persister formation.

Susceptibility of the srRNA deletion mutants to different antibiotics

To determine the role of the seven upregulated srRNAs in persistence, we constructed their deletion mutants ($\Delta micF$, $\Delta omrB$, $\Delta rybB$, $\Delta mcaS$, $\Delta micL$, $\Delta rdlB$, $\Delta rydB$) in the

uropathogenic *E. coli* strain UTI89 and tested their persister phenotypes to different classes of antibiotics. We monitored the numbers of the parent strain and all the deletion mutants without any antibiotic or stress exposure from the beginning to the end of the experiments and no difference was observed between the parent strain and the mutant strains (data not shown). In the log phase cultures ($\sim 10^8$ CFU/mL), when all the bacteria were challenged with gentamicin (30 μ g/mL), $\Delta mcaS$, $\Delta rydB$ and $\Delta micL$ mutants showed decreased persister numbers, ranging from 7-fold ($\Delta micL$) to 10-fold ($\Delta mcaS$) difference compared with the parent strain, whereas the other mutants were not affected (Fig. 3A). When exposed to cefotaxime (128 μ g/mL), all the mutants showed a decrease in persistence compared with the parent strain UTI89, ranging from 8-fold ($\Delta rdlB$) to 170-fold ($\Delta mcaS$) (Fig. 3B). The log phase cultures were also treated with levofloxacin for 0.5 h, and there was about 5-log decrease in all the tested strains, with no difference observed between the deletion mutants and the parent strain (data not shown).

However, when the stationary phase cultures were exposed to levofloxacin for two days, the persister phenotype could be observed. $\Delta rydB$ mutant showed a dramatic increase in persistence (Fig. 3C). After exposure to levofloxacin for six days, it could be observed that another deletion mutant ($\Delta rybB$) had a decreased persister phenotype (Fig. 3D), indicating *rybB* could be a late persister gene. When the seven srRNAs deletion mutants were treated with gentamicin for two days, $\Delta rybB$ and $\Delta micF$ mutants had prominent decrease in persistence compared to the parent strain UTI89 (Fig. 3E), while the $\Delta omrB$ mutant demonstrated persister defect at day 3 (Fig. 3F). After exposure to cefotaxime, the $\Delta micL$ mutant showed defect in persister formation, whereas the $\Delta rydB$ mutant showed increased persister-formation level at day 4 (Fig. 3G). The $\Delta omrB$ mutant also had lower persister number upon cefotaxime treatment at day 6 (Fig. 3H).

Susceptibility of the srRNA deletion mutants to stresses

To determine the effect of stresses on the survival of the srRNA deletion mutants, we subjected all the seven mutants to hyperosmosis (NaCl, 4M), acid (pH 3.0), heat (53°C) and oxidative (H_2O_2 , 10 mM) stresses and assessed their survival in the stationary phase (Fig. 4). Upon exposure to hyperosmosis for five days, only the $\Delta micL$ mutant showed dramatic decrease in survival (208-fold decrease) compared with the parent strain UTI89. No difference could be observed between the other deletion mutant strains and the parent strain (Fig. 4A). When treated with acid, four deletion mutants ($\Delta micL$, $\Delta omrB$, $\Delta rdlB$, $\Delta rybB$) showed higher susceptibilities (at least 16-fold decrease) compared with the parent strain, while the other three deletion mutants ($\Delta micF$, $\Delta mcaS$, $\Delta rydB$) had similar susceptibilities as the parent strain (Fig. 4B). Upon exposure to heat, five deletion mutants ($\Delta micL$, $\Delta omrB$, $\Delta micF$, $\Delta rdlB$, $\Delta rybB$) showed higher susceptibilities (at least 13-fold decrease) when compared with the parent strain (Fig. 4C). When all the deletion mutants were subjected to H_2O_2 oxidative stress, the survival of the five deletion mutant strains ($\Delta rdlB$, $\Delta micL$, $\Delta rydB$,

ΔmicF, *ΔmcaS*) was significantly decreased, whereas the other two mutants (*ΔomrB*, *ΔrybB*) showed the same magnitude of decrease as the parent strain (Fig. 4D).

Effects of the overexpression of srRNAs on persister levels

The seven srRNAs (*ΔmicF*, *ΔomrB*, *ΔrybB*, *ΔmcaS*, *ΔmicL*, *ΔrdlB*, *ΔrydB*) were overexpressed to further characterize their effects on persistence. The newly constructed plasmids carrying the corresponding srRNAs along with the empty vector pBAD202 were transformed into parent strain UTI89 for construction of the overexpression strains. In the stationary phase cultures, we found the five srRNAs (*MicF*, *MicL*, *OmrB*, *RdlB*, *RybB*) overexpression strains showed higher persister levels than the control strain upon exposure to levofloxacin (5 μg /mL), gentamicin (30 μg /mL), cefotaxime (128 μg /mL) and various stresses hyperosmosis (NaCl, 4M), acid (pH, 3.0), heat (53°C), and oxidative stress (H₂O₂, 10 mM), respectively. However, the *RydB* overexpression strain resulted in decreased persister levels to levofloxacin, cefotaxime, hyperosmosis and heat exposure, but showed increased persister levels to gentamicin, acid and oxidation treatment. The *McaS* overexpression strain also demonstrated higher persister-formation capabilities to levofloxacin, cefotaxime, gentamicin and stresses hyperosmosis, acid and oxidation exposure, whereas it had defect when challenged with heat stress (Table 2-3). Overall, all of the seven srRNAs have varying effects on persister-formation when overexpressed.

Impact of the srRNA mutations on biofilm formation

Because the presence of persister cells in the biofilm contributes largely to the recalcitrance to antibiotic treatment [30-33], we determined the influence of the persister-associated srRNAs on biofilm-formation. Interestingly, the results showed all the deletion mutants (*ΔmicF*, *ΔomrB*, *ΔrybB*, *ΔmcaS*, *ΔmicL*, *ΔrdlB*, *ΔrydB*) had reduced biofilm formation to some degree compared with the parent strain UTI89 (Fig. 5). Among them, the *ΔmcaS* mutant was the weakest (~21% decrease) while the *ΔmicF* mutant had the strongest effect on biofilm formation (~40% decrease) compared with the parent strain UTI89.

Discussion

In this study, we identified seven novel srRNAs (*MicF*, *OmrB*, *RybB*, *McaS*, *MicL*, *RdlB*, *RydB*) associated with persister formation in the uropathogenic *E. coli* strain UTI89. To our knowledge, this is the first study that comprehensively characterized the role of srRNA in persister formation. By comparing different expression levels of srRNAs in the three important timepoints S1, S2 and S3 relevant to persister formation, we identified initial natural persister formation related srRNAs (*MicF*, *OmrB*, *RybB*, *McaS*, *MicL*, *RdlB*, *RydB*) in the absence of antibiotic background. Because persisters are produced by a stochastic process [8, 34], monitoring the expression levels of genes after antibiotic treatment to search for persister-associated

genes is not suitable, as genes could be induced by antibiotics thereby confounding the real important persister formation genes [35]. By using this new persister gene search methodology comparing the expression of srRNAs at different critical stage of no persister and persister emergence in our study, we were able to find seven native srRNAs (MicF, OmrB, RybB, McaS, MicL, RdlB, RydB) involved in type II persister formation.

Apart from their roles in exponential phase persister-formation (Fig. 3A, 3B), we found the seven srRNAs are also involved in persistence in stationary phase (Fig. 3C-3H, Fig. 4 and Table 2-3). This phenomenon suggests that srRNAs fulfill their persistence function in the whole life span of the bacteria and confirms that srRNAs play a vital role in persistence to different antibiotics and stresses.

McaS is a multi-cellular adhesive small regulatory RNA and is known to regulate flagellar motility and biofilm formation by targeting the global transcription regulators (*csgD*, *flhD*) and biofilm formation related mRNA *pgaA* [27, 36]. Protein co-purification study also found that McaS could bind with RpsA (translation initiation factor), Lon (DNA-binding ATP-dependent protease), PNPase (polynucleotide phosphorylase or - polymerase), AtpA (F1 sector of membrane-bound ATP synthase), CsrA (Regulatory McaS protein for carbon source metabolism) [37]. The targets of McaS match well to the known persister pathways including global regulator, biofilm formation, trans-translation, protease and energy production [7], which can count for the role of McaS in persistence. Notably, Lon protease can also be regulated by McaS. As we know, polyphosphated Lon protease can cause the degradation of antitoxins and the freed toxin, subsequently turning bacteria into dormant persisters [38, 39]. This suggests that McaS may also influence TA modules for persister formation.

MicF inhibits ribosome binding and induce the degradation of the RNA messages in many bacteria [40]. MicF can interact with *lrp* (a global regulator involved in amino acid biosynthesis and catabolism), and down-regulate translation of *ompF* (outer membrane porin), *soxS* (DNA-binding transcriptional dual regulator) and *tolC* (a central factor involved in efflux pump) [41], which can be important for persister formation and survival [41, 42]. By serving as a well known antisense RNA of *ompF*, MicF can down-regulate *ompF* to reduce the entry of antibiotics so persisters can survive. Pathways of these targets are involved in global regulator, biofilm formation and efflux pump activity. We propose that MicF may influence the persister pathways to cause persistence to antibiotics and stresses via its target genes. It has been shown different expression levels of MicF in response to osmolarity and temperature change [43], and our observation that MicF mutant has defective persistence to hyperosmosis and heat exposure is consistent with the previous study.

MicL was reported to have a sole target *lpp*, an abundant outer membrane lipoprotein in response to stress [44]. We suppose that MicL may influence *lpp* expression to

affect transport of antibiotics and other stressors, thus facilitating persistence. In addition, using the updated tools CopraRNA and IntaRNA software for small RNA target prediction [45], we found MicL has binding sites with *mazF* (mRNA interferase toxin antitoxin) and *hipB* (HipB antitoxin / DNA-binding transcriptional repressor), which are two known persister genes involved in TA modules, indicating that MicL could mediate persister formation via these antitoxins.

RybB can regulate the expression of membrane porins related mRNA (*ompC*, *ompD*, *ompW*, *ompF*, and *fadL*) [46, 47], a transcriptional regulator associated with biofilm formation (*csgD*) [48], and also modulate LPS biosynthesis [49]. Additionally, overexpression of *rybB* causes increased expression of *rpoS* (a global regulator involved in persister formation) [50] and decreased levels of *fumC* (a fumarase isozyme participating in the TCA cycle) [46]. Thus, the targets of RybB match known persister pathways including those of biofilm formation, global regulators, and energy production [7], which could all account for persister phenotype of RybB.

The *omrB* deletion mutant showed defect in persistence when challenged with multiple antibiotics and stresses in both exponential phase and stationary phase cultures (Fig. 3-4). OmrB is known to regulate the expression levels of genes encoding many outer membrane proteins, including *cirA*, *fecA*, *fepA* and *ompT*, *ompR* [51], which could modulate outer membrane composition in response to environmental stress conditions. In addition, two transcriptional regulators *csgD* (important for biofilm formation) and *flhDC* together with a gluconate /fructuronate transporter *gntP* could also be modulated by OmrB [51-53]. Thus, we propose that OmrB can affect different persister pathways involved in biofilm, translational regulator and transport system to perform its persister function via its target genes.

To date, little is known about the functions of RdlB except that overexpression of RdlB decreases swarming motility and curli expression [54]. In this study, we demonstrated that RdlB is involved in persistence to antibiotics (levofloxacin, gentamicin, cefotaxime) and stresses (hyperosmosis, heat, oxidation, acid) for the first time (Fig. 3-4, Table 2-3). In order to investigate the mechanisms involved, we used the updated tools CopraRNA and IntaRNA for RdlB target prediction [45]. Results showed that RdlB has binding sites with energy production mRNA *srmB* (ATP-dependent RNA helicase), *paaH* (3-hydroxyadipyl-CoA dehydrogenase NAD⁺-dependent), transport system mRNA *nirC* (nitrite transporter), *ssuB* (aliphatic sulfonate ABC transporter ATPase), *potH* (putrescine ABC transporter permease), *nirD* (nitrite reductase NADH small subunit) and membrane associated mRNA *ybhM* (BAX Inhibitor-1 family inner membrane protein), *viaT* (putative outer membrane protein), *pqiA* (inner membrane protein) as well as DNA repair mRNA *vsr* (DNA mismatch endonuclease of very short patch repair). The associated pathways of these targets are known to be associated with persistence [7]. Notably, RdlB could also bind to *tnaA*, a well-known persister gene connected to signaling pathway. Future studies are needed to confirm how RdlB is involved in persister formation.

So far, RydB is known to regulate *rpoS* (a global regulator involved in persister formation) expression only [55]. In our study, we found RydB could modulate persister formation when treated with antibiotics and lethal stresses. Using small RNA target prediction CopraRNA and IntaRNA software analysis [45], we found RydB could affect persister pathways [7] via energy production mRNA *sdhA* (succinate dehydrogenase flavoprotein subunit), *purC* (amidophosphoribosyltransferase), *yjfC* (ATP-Grasp family ATPase), *cbrA* (FAD-binding protein putative oxidoreductase), membrane associated mRNA *ybbJ* (inner membrane protein), *asmA* (inner membrane-anchored), *yihG* (inner membrane protein inner membrane acyltransferase), *yobD* (UPF0266 family inner membrane protein), transport system mRNA *yncD* (putative iron outer membrane transporter), *artQ* (arginine ABC transporter permease), *fecC* (ferric citrate ABC transporter permease), *satP* (succinate-acetate transporter), efflux pump mRNA *mdtC* (multidrug efflux system subunit C), *ydhK* (putative efflux protein, component of YdhJK efflux pump) and trans-translation system *rpsA* mRNA. Among them, *sdhA* and *rpsA* are known persister genes [56, 57].

Biofilm can resist antibiotic killing without any drug resistance mechanisms. The link between the presence of persisters and biofilm formation is the subject of many studies [31, 32, 58, 59]. We propose that the roles of the srRNAs in persistence are associated with their biofilm formation capability, based on our findings. In line with this proposition, we found that the deletion mutants of the seven srRNAs all showed defective biofilm formation (Fig. 5). In particular, our finding of McaS is consistent with the previous finding that McaS is associated with biofilm formation [27]. However, the impacts of srRNA on attachment and secretion of extracellular polymeric substances to the biofilm remains further study.

In summary, we identified seven new small regulatory RNAs (OmrB, RdlB, McaS, MicF, MicL, RybB, and RydB) that are involved in persister formation using a novel persister gene search methodology. The targets of these small regulatory RNAs involved in several persister pathways including energy production, transport system, SOS response, DNA repair, TA module, biofilm formation, global regulator, trans-translation system, and efflux pump. Future studies are needed to address the role of srRNAs in persister formation in other bacteria and *in vivo* as well as the exact mechanisms by which srRNAs regulate the persistence phenomenon. Our findings provide new insights into mechanisms of persister formation and its regulation at the srRNA level and offer new targets for treatment of persistent infections.

Conflict of Interest Statement

The authors declare that this research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

383 Author Contributions

384 YZ, WZ designed the experiments and revised the manuscript; SZ and SL completed
385 all the experiments, SZ and NW performed the data analysis; SZ and YZ wrote the
386 manuscript.

387 Acknowledgments

388 We thank Peng Cui, Tao Xu, Jing Wu and Jiazhen Chen, at Department of Infectious
389 Diseases, Huashan Hospital, China for helpful advice in data analysis. The research
390 was supported by the National Natural Science Foundation of China (81572046).

391 Table 1. Target genes of the upregulated srRNAs.

srRNA Name	Target gene name	Description of target gene	Pathway of target gene
MicF	<i>lrp</i>	DNA-binding transcriptional dual regulator	global regulator
	<i>ompF</i>	outer membrane porin F	biofilm formation
	<i>tolC</i>	outer membrane channel TolC	efflux pump
	<i>cptA</i>	membrane-associated protein	TA module
	<i>hsdS</i>	type I restriction enzyme EcoKI specificity protein	
	<i>zwF</i>	NADP ⁺ -dependent glucose-6-phosphate dehydrogenase	energy production
	<i>phoE</i>	outer membrane porin E	biofilm formation
	<i>soxS</i>	DNA-binding transcriptional dual regulator	global regulator
MicL	<i>lpp</i>	murein lipoprotein	
MgrR	<i>eptB</i>	phosphoethanolamine transferase	
OmrB	<i>ompR</i>	DNA-binding transcriptional dual regulator	biofilm formation
	<i>ompT</i>	Outer membrane protease VII	biofilm formation
	<i>cirA</i>	ferric dihydroxybenzoylserine outer membrane transporter	transport system
	<i>fecA</i>	ferric citrate outer membrane transporter	transport system
	<i>fepA</i>	ferric enterobactin outer membrane transporter	transport system
	<i>flhDC</i>	DNA-binding transcriptional dual	biofilm formation

		regulator	
	<i>gntP</i>	fructuronate transporter	transport system
	<i>csgD</i>	DNA-binding transcriptional dual	biofilm formation
		regulator	
McaS	<i>csgD</i>	DNA-binding transcriptional dual	biofilm formation
		regulator	
	<i>csrA</i>	carbon storage regulator	global regulator
	<i>flhD</i>	DNA-binding transcriptional dual	biofilm formation
		regulator	
	<i>pgaA</i>	partially <i>N</i> -deacetylated poly- β -1,6- <i>N</i> -acetyl-D-glucosamine outer membrane porin	biofilm formation
	<i>rpsA</i>	30S ribosomal subunit protein S1	trans-translation
	<i>lon</i>	Lon protease	protease
	<i>pnP</i>	polynucleotide phosphorylase	energy production
	<i>atpA</i>	ATP synthase F ₁ complex subunit α	energy production
	<i>sda</i>	cysteine sulfinase desulfinate	
RybB	<i>waaR</i>	UDP-glucose:(glucosyl) LPS α -1,2-glucosyltransferase	energy production
	<i>rpoS</i>	RNA polymerase, sigma S (sigma 38) factor	global regulator
	<i>csgD</i>	DNA-binding transcriptional dual	biofilm formation
		regulator	
	<i>rpoE</i>	RNA polymerase, sigma 24 (sigma E) factor	global regulator
	<i>ompC,D, F, W</i>	outer membrane porinC, D, F, W	biofilm formation
	<i>fadL</i>	long-chain fatty acid outer membrane porin	energy production
	<i>fumC</i>	fumarate C	energy production
RydB	<i>rpoS</i>	RNA polymerase, sigma S (sigma 38) factor	global regulator
RseX	<i>ompA,C</i>	outer membrane porin A, C	biofilm formation
MicA	<i>ompA,X</i>	outer membrane porin A,X	biofilm formation
	<i>phoP</i>	DNA-binding transcriptional dual	global regulator
		regulator	
	<i>phoQ</i>	bifunctional sensory histidine kinase	
DicF	<i>ftsZ</i>	cell division protein	
	<i>xylR</i>	DNA-binding transcriptional dual	global regulator
		regulator	
	<i>pykA</i>	pyruvate kinase II	energy production
	<i>rpoS</i>	RNA polymerase, sigma S (sigma 38) factor	global regulator
ArrS	<i>gadE</i>	DNA-binding transcriptional	global regulator

activator	
RyeG	Unknown
RdlB	Unknown

392

393 **Table 2. Effect of overexpression of srRNAs on persister levels upon antibiotic**
394 **exposure**

Overexpression strains	No. of bacteria (Log CFU/mL)			
	Starting CFU	LVX	GEN	CTX
UTI89-Pvector	9.4±0.12	3.3±0.21	2.5±0.45	6.1±0.09
UTI89-PmcaS	9.8±0.05	5.3±0.07	4.2±0.13	7.9±0.13
UTI89-PrdlB	9.7±0.05	6.0±0.02	4.6±0.08	8.0±0.10
UTI89-PrydB	9.7±0.04	2.2±0.18	5.3±1.55	0
UTI89-PomrB	9.8±0.02	6.1±0.06	3.9±0.28	8.1±0.02
UTI89-PmicL	9.8±0.02	5.4±0.63	4.0±0.42	7.8±0.03
UTI89-PrybB	9.8±0.03	5.0±0.14	4.2±0.09	7.6±0.06
UTI89-PmicF	9.8±0.03	5.1±0.13	5.2±0.12	8.0±0.04

395 Stationary phase bacteria (~10⁹ CFU/mL) were challenged with levofloxacin (LVX, 5
396 µg/mL), gentamicin (GEN, 30 µg/mL) and cefotaxime (CTX, 128 µg/mL),
397 respectively, for five days. CFU values were determined at the appropriate times.

398 **Table 3. Effect of overexpression of srRNAs on persister levels upon stress**
399 **exposure.**

Overexpression strains	No. of bacteria (Log CFU/mL)				
	Starting CFU	Hyper-osmosis	Acid	Heat	H ₂ O ₂
UTI89-Pvector	9.4±0.12	3.6±0.41	2.8±0.06	3.9±0.17	4.1±0.17
UTI89-PmcaS	9.8±0.05	7.8±0.40	4.0±0.08	2.0±0.25	5.9±0.22
UTI89-PrdlB	9.7±0.05	7.7±0.26	4.0±0.09	4.4±0.13	4.9±0.20
UTI89-PrydB	9.7±0.04	1.0±0.68	3.5±0.15	2.2±0.80	5.1±0.08
UTI89-PomrB	9.8±0.02	7.8±0.52	3.9±0.08	5.5±0.13	4.9±0.28
UTI89-PmicL	9.8±0.02	8.0±0.55	3.8±0.16	6.0±0.18	4.9±0.25
UTI89-PrybB	9.8±0.03	7.7±0.49	4.1±0.08	5.6±0.07	5.3±0.85
UTI89-PmicF	9.8±0.03	7.8±0.86	3.6±0.07	5.5±0.20	4.9±0.14

400 Stationary phase bacteria (~10⁹ CFU/mL) were directly treated with various stresses.
401 For hyperosmosis or acid pH stress, the stationary phase bacteria were harvested,
402 washed and then resuspended in hyperosmotic LB medium (NaCl, 4M) for three days
403 as well as in acid LB medium (pH, 3.0) for one day. For heat, bacteria were directly

put in a water bath of 53°C for one hour. For oxidative stress, bacteria were 1:100 diluted before exposure to 10 mM H₂O₂ for 0.5 hour. CFU values were determined at the appropriate times.

Figure legends:

Fig. 1. Determination of three timepoints for persister formation upon ampicillin treatment. (A) Persister numbers at each hour. Overnight *E. coli* K-12 W3110 was 1:10⁵ diluted into fresh LB medium and then incubated at 37°C, 100 rpm. At each hour, aliquots were taken and exposed to ampicillin (100 µg/mL) for 3 hours to determine persister numbers. (B) The initial cell count. At the indicated hour, aliquots were taken without any treatment to determine the cell numbers directly. The experiments were performed in triplicate, and error bars represent standard deviations.

Fig. 2. Upregulated small regulatory RNAs in S2/S1 and S3/S1. Overnight *E. coli* K-12 W3110 was 1:10⁵ diluted into fresh LB medium and then incubated at 37°C, 100 rpm up to S1 (3 hours), S2 (4 hours) and S3 (5 hours), respectively. And then, total RNA was extracted and used for qRT-PCR. Upregulated small regulatory RNAs when comparing srRNA expression levels in S2/S1 (A), S3/S1 (B) are shown. The error bars show standard deviations (n=3).

Fig. 3. Susceptibility of the srRNA deletion mutants to antibiotics. (A, B) Susceptibilities of the log phase bacteria to gentamicin (30 µg/mL, A) or cefotaxime (128 µg/mL, B) after exposure for six hours. (C, D) Susceptibilities of the stationary phase bacteria to levofloxacin (5 µg/mL) on the second day (C) or the sixth day (D). (E, F) Susceptibilities of the stationary phase bacteria to gentamicin (30 µg/mL) on the second day (E) or the third day (F). (G, H) Susceptibilities of the stationary phase bacteria to cefotaxime (128 µg/mL) on the fourth day (G) or the sixth day (H). Bacteria were cultured to log phase (~10⁸ CFU/mL) or stationary phase (~10⁹ CFU/mL) prior to the addition of antibiotics. The number of persisters was determined at the time point indicated in the figure. The error bars show standard deviations (n=3). * Indicates significant difference from the other strains at *p* < 0.05.

Fig. 4. Susceptibility of the srRNA deletion mutants to stresses. (A) Susceptibilities to hyperosmosis (NaCl, 4 M) after exposure for five days. (B) Susceptibilities to acid (pH 3.0) after exposure for one day. (C) Susceptibilities to heat (53°C) after exposure for two hours. (D) Susceptibilities to oxidative stress (H₂O₂, 10 mM) after exposure for 0.5 hour. Bacteria were cultured to the stationary phase (~10⁹ CFU/mL) prior to the addition of stresses. Detailed methods were described above. The error bars show standard deviations (n=3). * Indicates significant difference from the other strains at *p* < 0.05.

Fig. 5. Effect of the deletion mutants on biofilm formation. 200 µl bacteria were transferred to 96-well microtiter plates and grown at 37°C for 24 h in LB medium. Planktonic cells were measured at OD₆₀₀. After washing, staining with crystal violet, and dissolution, final biofilm formation was measured at OD₅₇₀ and normalized to OD₆₀₀.

References

1. Bigger, J.W., *Treatment of staphylococcal infections with penicillin - By intermittent sterilisation*. Lancet, 1944. 2: p. 497-500.
2. Ramirez, M., et al., *Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells*. Nature Communications, 2016. 7.
3. Ma, C., et al., *Energy production genes *sucB* and *ubiF* are involved in persister survival and tolerance to multiple antibiotics and stresses in *Escherichia coli**. Fems Microbiology Letters, 2010. 303(1): p. 33-40.
4. Ford, A.M., et al., *Protracted dormancy of pre-leukemic stem cells*. Leukemia, 2015. 29(11): p. 2202-7.
5. Raha, D., et al., *The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation*. Cancer Res, 2014. 74(13): p. 3579-90.
6. Dawson, C.C., C. Intapa, and M.A. Jabra-Rizk, *"Persisters": Survival at the Cellular Level*. Plos Pathogens, 2011. 7(7).
7. Zhang, Y., *Persisters, persistent infections and the Yin-Yang model*. Emerg Microbes Infect, 2014. 3(1): p. e3.
8. Lewis, K., *Persister cells, dormancy and infectious disease*. Nature Reviews Microbiology, 2007. 5(1): p. 48-56.
9. Levin-Reisman, I., et al., *Antibiotic tolerance facilitates the evolution of resistance*. Science, 2017. 355(6327): p. 826-830.
10. Torrey, H.L., et al., *High Persister Mutants in *Mycobacterium tuberculosis**. Plos One, 2016. 11(5).
11. LaFleur, M.D., Q.G. Qi, and K. Lewis, *Patients with Long-Term Oral Carriage Harbor High-Persister Mutants of *Candida albicans**. Antimicrobial Agents And Chemotherapy, 2010. 54(1): p. 39-44.
12. Balaban, N.Q., et al., *Bacterial persistence as a phenotypic switch*. Science, 2004. 305(5690): p. 1622-5.
13. Keren, I., et al., *Persister cells and tolerance to antimicrobials*. Fems Microbiology Letters, 2004. 230(1): p. 13-18.
14. Babski, J., et al., *Small regulatory RNAs in Archaea*. Rna Biology, 2014. 11(5): p. 484-493.
15. Lalaouna, D., et al., *Regulatory RNAs and target mRNA decay in prokaryotes*. Biochim Biophys Acta, 2013. 1829(6-7): p. 742-7.
16. Waters, L.S. and G. Storz, *Regulatory RNAs in bacteria*. Cell, 2009. 136(4): p. 615-28.
17. Michaux, C., et al., *Physiological roles of small RNA molecules*.

483 Microbiology, 2014. 160(Pt 6): p. 1007-19.

484 18. Han, R., et al., *A Small Regulatory RNA Contributes to the Preferential*

485 *Colonization of Escherichia coli O157:H7 in the Large Intestine in Response*

486 *to a Low DNA Concentration*. Front Microbiol, 2017. 8: p. 274.

487 19. Gimpel, M. and S. Brantl, *Dual-function small regulatory RNAs in bacteria*.

488 Mol Microbiol, 2017. 103(3): p. 387-397.

489 20. Georg, J., et al., *The small regulatory RNA SyR1/PsrR1 controls*

490 *photosynthetic functions in cyanobacteria*. Plant Cell, 2014. 26(9): p. 3661-79.

491 21. Sudo, N., et al., *A novel small regulatory RNA enhances cell motility in*

492 *enterohemorrhagic Escherichia coli*. J Gen Appl Microbiol, 2014. 60(1): p.

493 44-50.

494 22. van der Meulen, S.B., A. de Jong, and J. Kok, *Transcriptome landscape of*

495 *Lactococcus lactis reveals many novel RNAs including a small regulatory*

496 *RNA involved in carbon uptake and metabolism*. RNA Biol, 2016. 13(3): p.

497 353-66.

498 23. Datsenko, K.A. and B.L. Wanner, *One-step inactivation of chromosomal genes*

499 *in Escherichia coli K-12 using PCR products*. Proc Natl Acad Sci U S A,

500 2000. 97(12): p. 6640-5.

501 24. Li, J.H., et al., *Trans-translation mediates tolerance to multiple antibiotics and*

502 *stresses in Escherichia coli*. Journal Of Antimicrobial Chemotherapy, 2013.

503 68(11): p. 2477-2481.

504 25. Li, Y. and Y. Zhang, *PhoU is a persistence switch involved in persister*

505 *formation and tolerance to multiple antibiotics and stresses in Escherichia*

506 *coli*. Antimicrob Agents Chemother, 2007. 51(6): p. 2092-9.

507 26. Wang, W.J., et al., *Transposon Mutagenesis Identifies Novel Genes Associated*

508 *with Staphylococcus aureus Persister Formation*. Frontiers In Microbiology,

509 2015. 6.

510 27. Thomason, M.K., et al., *A small RNA that regulates motility and biofilm*

511 *formation in response to changes in nutrient availability in Escherichia coli*.

512 Molecular Microbiology, 2012. 84(1): p. 17-35.

513 28. Wu, N., et al., *Ranking of persister genes in the same Escherichia coli genetic*

514 *background demonstrates varying importance of individual persister genes in*

515 *tolerance to different antibiotics*. Frontiers In Microbiology, 2015. 6.

516 29. Keseler, I.M., et al., *The EcoCyc database: reflecting new knowledge about*

517 *Escherichia coli K-12*. Nucleic Acids Research, 2017. 45(D1): p. D543-D550.

518 30. Urish, K.L., et al., *Antibiotic-tolerant Staphylococcus aureus Biofilm Persists*

519 *on Arthroplasty Materials*. Clinical Orthopaedics And Related Research, 2016.

520 474(7): p. 1649-1656.

521 31. Attaran, B., T. Falsafi, and N. Ghorbanmehr, *Effect of biofilm formation by*

522 *clinical isolates of Helicobacter pylori on the efflux-mediated resistance to*

523 *commonly used antibiotics*. World Journal Of Gastroenterology, 2017. 23(7):

524 p. 1163-1170.

525 32. Babra, C., et al., *The persistence of biofilm-associated antibiotic resistance of*

526 *Staphylococcus aureus isolated from clinical bovine mastitis cases in*

- 527 *Australia. Folia Microbiologica*, 2013. 58(6): p. 469-474.
- 528 33. Mah, T.F., et al., *A genetic basis for Pseudomonas aeruginosa biofilm*
529 *antibiotic resistance*. *Nature*, 2003. 426(6964): p. 306-310.
- 530 34. Keren, I., et al., *Specialized persister cells and the mechanism of multidrug*
531 *tolerance in Escherichia coli*. *J Bacteriol*, 2004. 186(24): p. 8172-80.
- 532 35. Lewis, K., *Persister cells*. *Annu Rev Microbiol*, 2010. 64: p. 357-72.
- 533 36. Modi, S.R., et al., *Functional characterization of bacterial sRNAs using a*
534 *network biology approach*. *Proceedings Of the National Academy Of Sciences*
535 *Of the United States Of America*, 2011. 108(37): p. 15522-15527.
- 536 37. van Nues, R.W., et al., *Ribonucleoprotein particles of bacterial small*
537 *non-coding RNA IsrA (IS61 or McaS) and its interaction with RNA polymerase*
538 *core may link transcription to mRNA fate*. *Nucleic Acids Research*, 2016.
539 44(6): p. 2577-2592.
- 540 38. Maisonneuve, E., M. Castro-Camargo, and K. Gerdes, *(p)ppGpp controls*
541 *bacterial persistence by stochastic induction of toxin-antitoxin activity*. *Cell*,
542 2013. 154(5): p. 1140-1150.
- 543 39. Germain, E., et al., *Stochastic induction of persister cells by HipA through*
544 *(p)ppGpp-mediated activation of mRNA endonucleases*. *Proceedings Of the*
545 *National Academy Of Sciences Of the United States Of America*, 2015.
546 112(16): p. 5171-5176.
- 547 40. Delihias, N., *Discovery and characterization of the first non-coding RNA that*
548 *regulates gene expression, micF RNA: A historical perspective*. *World J Biol*
549 *Chem*, 2015. 6(4): p. 272-80.
- 550 41. Misra, R. and P.R. Reeves, *Role of micF in the tolC-mediated regulation of*
551 *OmpF, a major outer membrane protein of Escherichia coli K-12*. *J Bacteriol*,
552 1987. 169(10): p. 4722-30.
- 553 42. Lee, H.J. and S. Gottesman, *sRNA roles in regulating transcriptional*
554 *regulators: Lrp and SoxS regulation by sRNAs*. *Nucleic Acids Research*, 2016.
555 44(14): p. 6907-6923.
- 556 43. Coyer, J., et al., *micF RNA in ompB mutants of Escherichia coli: different*
557 *pathways regulate micF RNA levels in response to osmolarity and temperature*
558 *change*. *J Bacteriol*, 1990. 172(8): p. 4143-50.
- 559 44. Guo, M.S., et al., *MicL, a new sigma(E)-dependent sRNA, combats envelope*
560 *stress by repressing synthesis of Lpp, the major outer membrane lipoprotein*.
561 *Genes & Development*, 2014. 28(14): p. 1620-1634.
- 562 45. Wright, P.R., et al., *CopraRNA and IntaRNA: predicting small RNA targets,*
563 *networks and interaction domains*. *Nucleic Acids Research*, 2014. 42(W1): p.
564 W119-W123.
- 565 46. Gogol, E.B., et al., *Small RNAs endow a transcriptional activator with*
566 *essential repressor functions for single-tier control of a global stress regulon*.
567 *Proc Natl Acad Sci U S A*, 2011. 108(31): p. 12875-80.
- 568 47. Groszewska, A., Z. Wroblewska, and M. Olejniczak, *The structure of fadL*
569 *mRNA and its interactions with RybB sRNA*. *Acta Biochimica Polonica*, 2016.
570 63(4): p. 835-840.

- 571 48. Serra, D.O., et al., *The green tea polyphenol EGCG inhibits E-coli biofilm*
572 *formation by impairing amyloid curli fibre assembly and downregulating the*
573 *biofilm regulator CsgD via the sigma(E)-dependent sRNA RybB*. Molecular
574 Microbiology, 2016. 101(1): p. 136-151.
- 575 49. Klein, G. and S. Raina, *Regulated Control of the Assembly and Diversity of*
576 *LPS by Noncoding sRNAs*. Biomed Research International, 2015.
- 577 50. Wassarman, K.M., et al., *Identification of novel small RNAs using comparative*
578 *genomics and microarrays*. Genes Dev, 2001. 15(13): p. 1637-51.
- 579 51. Guillier, M. and S. Gottesman, *Remodelling of the Escherichia coli outer*
580 *membrane by two small regulatory RNAs*. Molecular Microbiology, 2006.
581 59(1): p. 231-247.
- 582 52. Mika, F. and R. Hengge, *Small RNAs in the control of RpoS, CsgD, and*
583 *biofilm architecture of Escherichia coli*. RNA Biol, 2014. 11(5): p. 494-507.
- 584 53. Tjaden, B., et al., *Target prediction for small, noncoding RNAs in bacteria*.
585 Nucleic Acids Res, 2006. 34(9): p. 2791-802.
- 586 54. Bak, G., et al., *Identification of novel sRNAs involved in biofilm formation,*
587 *motility, and fimbriae formation in Escherichia coli*. Sci Rep, 2015. 5: p.
588 15287.
- 589 55. Komasa, M., et al., *A screening system for artificial small RNAs that inhibit*
590 *the growth of Escherichia coli*. Journal Of Biochemistry, 2011. 150(3): p.
591 289-294.
- 592 56. Wang, W., et al., *Transposon Mutagenesis Identifies Novel Genes Associated*
593 *with Staphylococcus aureus Persister Formation*. Front Microbiol, 2015. 6.
- 594 57. Shi, W.L., et al., *Pyrazinamide Inhibits Trans-Translation in Mycobacterium*
595 *tuberculosis*. Science, 2011. 333(6049): p. 1630-1632.
- 596 58. Harrison, J.J., R.J. Turner, and H. Ceri, *Persister cells, the biofilm matrix and*
597 *tolerance to metal cations in biofilm and planktonic Pseudomonas aeruginosa*.
598 Environmental Microbiology, 2005. 7(7): p. 981-994.
- 599 59. Yadav, M.K., et al., *The Small Molecule DAM Inhibitor, Pyrimidinedione,*
600 *Disrupts Streptococcus pneumoniae Biofilm Growth In Vitro*. PLoS One, 2015.
601 10(10).

602

603

604

605

606

607

Fig. 1.

Fig. 2.

Fig. 3

Fig 4.

A

B

C

D

Fig 5.

642 **Table S1. Primers used to generate gene-knockout mutants.**

Gene	Primer (5'–3')
<i>rydB</i>	F: TCAGAAATAAGAAAACCCTTAAGTCTGTGCGACACAGGC TTAAGGGTTTGTGTAGGCTGGAGCTGCTTC R: AATAATACAAATCGCAGTTTGTGTTAAAACAGTGGGTAGC TTTATGAGATGGGAATTAGCCATGGTCC
<i>mcaS</i>	F: ATTCCCAATCCCGGCGAGAATGTGGTTAT TTACAGAGCT AAAAAATGAAGTGTAAGGCTGGAGCTGCTTC R: ACGGATGGGTAAAACCGTTATAACACTGTCACCGGTCACCAGG ACCCCAG ATGGGAATTAGCCATGGTCC
<i>rybB</i>	F: GATTTTGAGGATGGTTGAGAGGATTGCTGGGTAGTAGATAA ATTTCAAGCGTGTAGGCTGGAGCTGCTTC R: TTTGCACAACCGCAGAACTTTCCGCAGGGCATCAGTCTTA ATTAGTGCCATGGGAATTAGCCATGGTCC
<i>micF</i>	F: CAGCACTGAATGTCAAAACAAAACCTTCACTCGCAACTAG AATAACTCCCGTGTAGGCTGGAGCTGCTTC R: ATAGTTTTTCTGTGGTAGCACAGAATAATGAAAAGTGTGT AAAGAAGGGTATGGAATTAGCCATGGTCC
<i>omrB</i>	F: TGCAACGAGGTGTGTAAATTGTCGGTACTGTTACAGATT GATGACCGGCGTGTAGGCTGGAGCTGCTTC R: TTGCGATTGACTGCTGGTGGCGTTTGGCTTCAGGTTGCTAA AGTGGTGATATGGGAATTAGCCATGGTCC

644

	F: CCCGCTCAAC AGATCACGGC AATCGTTCGT TTTTATACT GCTCAGGGATGTGTAGGCTGGAGCTGCTTC
<i>micL</i>	R: GCGGCGGTTGCTGAAATGAAAGGAATCATTGAACGCCATCAG GCCAAATGATGGGAATTAGCCATGGTCC
	F: AGCCGCCTTG TTGTAATGAC AACATTTTGC GGCTATTCTT GAATTGTTGA GTGTAGGCTGGAGCTGCTTC
<i>rdlB</i>	R: GCGCAATGTTGCGGGGGCTTTATCCCTGGTGGCATTGGTT GCTGGAAAG ATGGGAATTAGCCATGGTCC

645

646 **Table S2. Primers used to verify gene knockout mutants.**

Gene	Primer (5'–3')
<i>rydB</i>	F: TTCAGAAATA AGAAAACCCT R: AAATAATACAAATCGCAGTT
<i>mcaS</i>	F: ATTCCCCAAT CCCGGCGAGA R: ACGGATGGGTAAAACCGTTA
<i>rybB</i>	F: GATTTTGAGGATGGTTGAGA R: TTTGCACAACCGCAGAACTT
<i>micF</i>	F: CAGCACTGAATGTCAAAACA R: ATAGTTTTTCTGTGGTAGCA
<i>omrB</i>	F: TGCAACGAGGTGTGTAAATT R: TTGCGATTGACTGCTGGTGG
<i>micL</i>	F: CCCGCTCAAC AGATCACGGC R: GCGGCGGTTGCTGAAATGAA
<i>rdlB</i>	F: AGCCGCCTTG TTGTAATGAC R: GCGCAATGTTGCGGGGGCT

647

648

649

650

651 **Table S3. Primers used to generate overexpression strains.**

Gene	Primer (5'–3')
<i>rydB</i>	F: CATG CCATGG CTACCCCATCCGGCGCTT R: CCCG GAATTC ATTATCCTTATCGCCCCTTCA
<i>mcaS</i>	F: CATG CCATGG TAAAAAAATAGAGCCTGTCGAC R: CCCG GAATTC GCCGGATTTAAGACGAGGAT
<i>rybB</i>	F: CATG CCATGG GCCACTGCTTTTCTTTGATGT R: CCCG GAATTC ACAAAAAACCCATCAACCTTGA
<i>micF</i>	F: CATG CCATGG GCTATCATCATTAACCTTATTTATT R: CCCG GAATTC AAAAAAAACCGGATGCGAGGC
<i>omrB</i>	F: CATG CCATGG CCCAGAGGTATTGATAGGTG R: CCCG GAATTC AAAAAAAACCTGCGCATCTGC
<i>micL</i>	F: CATG CCATGG ATTTTACCGTTGCATCATGTC R: CCCG GAATTC AAAAAAAGGCCCTGTTGAAAT
<i>rdlB</i>	F: CATG CCATGG TGGTTCAAGATTAGCCCCCG R: CCCG GAATTC AGAAAACCCCCGCACGTTGA